Import from '@womanrx/ui'

Can I Take Quercetin with CJC-1295? A Women's Guide to This Combination

What Is CJC-1295 and Why Are Women Using It?

CJC-1295, also called Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors on the anterior pituitary, prompting a pulse of endogenous growth hormone release. Most formulations circulating through 503A compounding pharmacies are combined with ipamorelin, a ghrelin mimetic, to produce a more physiologic GH pulse. CJC-1295 with drug affinity complex (DAC) has a much longer half-life, roughly six to eight days, compared to the non-DAC version whose active window is around thirty minutes.

Women are turning to this peptide for a range of reasons: body composition during perimenopause, recovery from training, sleep quality, skin integrity, and the metabolic slowdown that accompanies estrogen decline. That is a meaningful clinical context, because women have sex-specific GH physiology that male-default peptide protocols almost never address.

How GH Physiology Differs in Women

Women secrete more GH per day than men, but in smaller, more frequent pulses, and they are more sensitive to GH suppression from elevated free fatty acids. Research published in the Journal of Clinical Endocrinology and Metabolism showed that mean 24-hour GH concentrations are significantly higher in premenopausal women than age-matched men, driven in part by estrogen's ability to amplify pituitary GH secretion. After menopause, that estrogen-driven amplification drops, contributing to the body-composition shift that many women notice.

The menstrual cycle itself modulates GH: the mid-cycle estrogen surge boosts GH pulse amplitude, while the luteal phase sees more stable but lower mean GH. This means that adding a GH secretagogue like CJC-1295 in the follicular phase may produce a noticeably different effect than the same dose in the luteal phase. No clinical trial has mapped CJC-1295 dosing across the menstrual cycle phases. That is a genuine evidence gap, and you deserve to know it.

What "Research/503A" Status Actually Means for You

CJC-1295 is not FDA-approved for any indication. It is available through 503A compounding pharmacies in the United States when prescribed by a licensed clinician. The FDA's 2023 guidance on peptide compounding has created a shifting regulatory environment: several peptides have been moved to or near the "demonstrably difficult to compound" list, so sourcing and legal status may change. Ask your prescriber for the most current status before filling.

What Is Quercetin and Why Do Women Take It?

Quercetin is a flavonoid polyphenol found in onions, capers, apples, and green tea. As a supplement it is popular for immune support, allergy symptom reduction, anti-inflammatory effects, and more recently as an adjunct in longevity and metabolic health protocols. Doses in studies range from 250 mg to 1,000 mg per day, with a 2016 meta-analysis in Nutrients reporting that doses at or above 500 mg per day produced statistically significant reductions in blood pressure in hypertensive populations.

Women specifically reach for quercetin during perimenopause and post-menopause because of its mild phytoestrogenic activity and its documented ability to inhibit aromatase at high concentrations in vitro. That aromatase-inhibiting effect sounds appealing on paper, but the in-vivo human data is thin, and the concentrations required in cell studies far exceed what typical oral supplementation achieves in serum.

Quercetin and Histamine: A Women's-Health Angle

One reason quercetin appears in women's health protocols is its ability to stabilize mast cells and reduce histamine release. A study in Molecules (2016) confirmed quercetin's capacity to inhibit histamine release from mast cells in vitro. This matters for women with PCOS, endometriosis, and mast cell activation syndrome, all conditions with elevated mast cell activity. If you are taking CJC-1295 partly because GH can improve lean mass in PCOS, and you are also taking quercetin for PCOS-related inflammation, you are squarely in the population where this combination gets used, and where the evidence gap is most pronounced.

Quercetin's Bioavailability Problem

Quercetin is notoriously poorly absorbed in its standard form. Bioavailability from food is roughly 24%, and from standard quercetin dihydrate supplements it is similar. Formulations bound to phytosomes (quercetin-phosphatidylcholine complexes) or complexed with bromelain improve absorption meaningfully. Why does this matter for interactions? Because higher bioavailability forms reach peak serum concentrations that are more pharmacologically relevant, meaning they are more likely to produce the CYP3A4 and P-glycoprotein effects discussed below.

The Interaction Mechanism: Pharmacokinetic vs. Pharmacodynamic

This is the section most articles skip. There are two distinct ways quercetin could interact with CJC-1295, and they work through completely different biology.

Pharmacokinetic Interaction: CYP3A4 and P-Glycoprotein Inhibition

CJC-1295 itself is a peptide. Peptides are primarily metabolized by proteolytic enzymes, not by hepatic cytochrome P450 enzymes like CYP3A4. So the direct pharmacokinetic concern is lower than it would be with a small-molecule drug. However, CYP3A4 is relevant to anything co-administered alongside CJC-1295 in the same protocol. Many women stacking CJC-1295 are simultaneously taking hormonal medications, thyroid drugs, or other supplements that are CYP3A4 substrates. Quercetin inhibits CYP3A4 and P-glycoprotein, as documented in a 2012 study in Drug Metabolism and Disposition, and that inhibition can raise the serum levels of CYP3A4-dependent drugs well above their intended range.

If you take any of the following alongside CJC-1295 and are considering adding quercetin, the CYP3A4 angle becomes clinically meaningful:

• Oral contraceptives (ethinyl estradiol is partially CYP3A4-metabolized)
• Progesterone (micronized progesterone, CYP3A4 substrate)
• Testosterone for female hypoactive sexual desire disorder
• Thyroid medications (less CYP3A4-dependent, but still worth noting)
• Sildenafil (used off-label for HSDD in some women)

The Natural Medicines database classifies the quercetin-CYP3A4 interaction as "moderate" for drugs that are sensitive CYP3A4 substrates. The relevant question for you is not just "is quercetin safe with CJC-1295" in isolation, but whether quercetin is safe with everything else in your protocol.

Pharmacodynamic Interaction: Histamine Pathways and GH Release

This is where the biology gets more specific to women. Histamine stimulates GH secretion through hypothalamic H1 receptors. Research in Neuroendocrinology demonstrated that histamine acts as a stimulatory signal in the GH release cascade in humans. Quercetin's antihistamine-like action, by blocking H1 receptors and reducing histamine availability, may theoretically blunt part of the GH secretion response that CJC-1295 is trying to amplify.

In practice, the magnitude of this effect in humans taking clinical doses of quercetin (500 to 1,000 mg per day) alongside CJC-1295 (typically 100 mcg to 300 mcg subcutaneously) has not been measured in any published trial. The pharmacodynamic interaction is biologically plausible, not confirmed. Women with baseline lower GH pulsatility (post-menopausal women, or those with hypothyroidism) may be more sensitive to any attenuation of GH response.

The WomanRx Interaction Classification for CJC-1295 and Quercetin:

| Interaction Type | Mechanism | Clinical Relevance | Evidence Level | |---|---|---|---| | Pharmacokinetic (direct) | CJC-1295 is peptide-metabolized; not a CYP3A4 substrate | Low for CJC-1295 itself | Mechanistic inference | | Pharmacokinetic (indirect) | Quercetin inhibits CYP3A4 and P-gp, affecting co-medications | Moderate if hormonal meds co-prescribed | Human pharmacology studies | | Pharmacodynamic | Quercetin antihistamine effect may attenuate GH pulse amplitude | Low to moderate; not clinically confirmed | Animal and in-vitro data | | Additive anti-inflammatory | Both have anti-inflammatory properties; likely beneficial overlap | Low risk; possibly additive benefit | Observational |

Who This Combination Is Right For (and Who Should Be More Cautious)

Your life stage and current health conditions change the risk-benefit calculation considerably.

Reproductive-Age Women (18-40)

If you are in your reproductive years and cycling regularly, the first question is contraception. CJC-1295 has no safety data in pregnancy and must not be used if you are trying to conceive or might become pregnant (see the pregnancy section below). Quercetin at high doses has shown anti-implantation effects in animal models, adding another layer of caution. If you are on oral contraceptives, quercetin's CYP3A4 inhibition could theoretically reduce the first-pass metabolism of ethinyl estradiol, slightly increasing its serum level. The clinical significance of this is unknown, but it is a reason to mention quercetin to your prescriber.

Women with PCOS who are using CJC-1295 for body composition and quercetin for inflammation or insulin sensitivity represent a realistic combined use case. A 2021 randomized controlled trial in Phytotherapy Research found that 1,000 mg of quercetin per day for 12 weeks improved insulin resistance and androgens in women with PCOS. That is promising, but the trial did not include any peptide co-administration.

Perimenopausal Women (40-55)

Perimenopause is arguably where this combination is most commonly explored. Declining estrogen reduces GH pulse amplitude, body composition shifts toward fat mass and away from lean mass, and inflammation rises. The theoretical rationale for using a GH secretagogue alongside an anti-inflammatory polyphenol makes intuitive sense.

The caution here involves thyroid function. Perimenopausal women have a higher incidence of autoimmune thyroid disease, and GH itself can unmask subclinical hypothyroidism by increasing T4-to-T3 conversion demands. If you are on levothyroxine, quercetin's effect on intestinal P-glycoprotein could in theory alter levothyroxine absorption if taken simultaneously. Separate levothyroxine from quercetin by at least four hours.

Post-Menopausal Women (55+)

Post-menopausal women have lower baseline GH and IGF-1 and may see more pronounced responses to CJC-1295. They also tend to carry more co-medications: statins, blood pressure medications, and hormone therapy. Statins such as atorvastatin and simvastatin are CYP3A4 substrates, and quercetin's inhibition of CYP3A4 has been shown to increase atorvastatin AUC by roughly 36% in a human pharmacokinetic study. That is a clinically meaningful increase in statin exposure.

If you are on menopausal hormone therapy, note that oral estradiol is partially CYP3A4-metabolized. Transdermal estradiol bypasses first-pass hepatic metabolism and is a safer choice from a drug-interaction standpoint.

Pregnancy, Lactation, and Contraception: Non-Negotiable Facts

CJC-1295 is not safe to use during pregnancy. This is not a gray area.

There are no human pregnancy safety data for CJC-1295 or any synthetic GHRH analogue. GH and IGF-1 are trophic hormones with dose-dependent effects on fetal and placental development. Exogenous manipulation of the GH axis during pregnancy carries theoretical teratogenic and growth-dysregulating risk. The Endocrine Society's clinical practice guideline on GH notes that GH replacement is discontinued during pregnancy even in women with confirmed adult growth hormone deficiency, precisely because the safety profile in pregnancy is unknown.

What you must do before starting CJC-1295:

• Confirm you are not pregnant with a urine or serum beta-hCG test.
• Use reliable contraception throughout the entire duration of use. Barrier methods alone are considered insufficient given the theoretical embryotoxic risk from GH-axis disruption. An IUD, hormonal method, or surgical contraception is appropriate.
• Discuss a plan to stop CJC-1295 at least three months before any planned pregnancy attempt, to allow GH and IGF-1 to normalize.

Quercetin in pregnancy: The safety data is similarly limited. High-dose quercetin showed embryotoxic effects in animal studies at doses far above typical supplemental ranges. A 2020 review in Foods classified quercetin as "probably safe at dietary levels" but noted that supplemental doses above 500 mg per day during pregnancy cannot be considered safe without human trial data. Avoid quercetin supplements during pregnancy and while trying to conceive.

Lactation: CJC-1295 has no lactation safety data. Peptides can transfer into breast milk, and GH-axis manipulation in a breastfeeding infant is not an acceptable risk. Do not use CJC-1295 while breastfeeding. Quercetin is present in breast milk when consumed as food; high-dose supplementation during lactation is not studied and is not recommended.

Practical Dosing, Timing, and Monitoring

Dose-Separation Strategy

Because CJC-1295 (non-DAC) has a short active window of 20 to 30 minutes post-injection and is administered subcutaneously, and quercetin exerts its CYP3A4 inhibition primarily during intestinal absorption (typically one to three hours after oral ingestion), the simplest separation strategy is:

• Take quercetin with breakfast or lunch.
• Administer CJC-1295 at bedtime, which is also the recommended timing to align with the natural nocturnal GH surge.

This two-to-four-hour minimum separation reduces any overlap in peak pharmacological activity. It does not eliminate the pharmacodynamic concern entirely, since quercetin's antihistamine effects persist for several hours, but it is the most pragmatic approach available given the evidence base.

What to Monitor

If your clinician has prescribed CJC-1295 and you are adding quercetin, request baseline and follow-up labs:

• IGF-1 (insulin-like growth factor 1): primary marker of GH response to CJC-1295. If IGF-1 fails to rise as expected after four to six weeks, the blunted response could reflect quercetin's antihistamine effect or simply poor CJC-1295 absorption.
• Fasting glucose and insulin: GH is insulin-antagonistic, and quercetin has insulin-sensitizing properties. The net effect in an individual woman is not predictable. A 2019 trial in the European Journal of Nutrition showed that 500 mg per day of quercetin for eight weeks improved fasting glucose by a mean of 5.6 mg/dL in metabolically at-risk adults.
• Lipid panel: if you are also on a statin, monitor for statin-related myopathy symptoms and consider a lipid panel at six to eight weeks after adding quercetin.
• Thyroid function (TSH, free T4): particularly in perimenopausal and post-menopausal women starting GH secretagogue therapy.

Starting Doses Typically Used in Women's Health Protocols

These are the doses seen in compounding pharmacy protocols for women; they are not FDA-approved doses, and individual prescriptions vary:

| Agent | Typical Starting Dose | Route | Timing | |---|---|---|---| | CJC-1295 (non-DAC) | 100 mcg | Subcutaneous injection | At bedtime | | CJC-1295 + Ipamorelin blend | 100/100 mcg | Subcutaneous injection | At bedtime | | Quercetin | 500 mg | Oral | Morning with food |

What the Evidence Gap Really Means for You

Women have been underrepresented in peptide research. The foundational CJC-1295 pharmacokinetic work, including the 2006 study by Jetté et al. In the Journal of Clinical Endocrinology and Metabolism showing that CJC-1295 with DAC produced sustained GH elevation for up to six days, enrolled mostly men. The pharmacodynamic data on quercetin's antihistamine and CYP enzyme effects also comes primarily from male-enrolled or mixed-sex studies without sex-stratified analysis.

This means that when you ask "is quercetin safe with CJC-1295," the honest answer is that no study has tested this combination in women, in men, or in any population. The interaction assessment draws on:

1. The known mechanism of CJC-1295 (GHRH-receptor agonism, peptidase-mediated clearance)
2. The known pharmacology of quercetin (CYP3A4/P-gp inhibition, mast cell stabilization, H1 receptor antagonism)
3. The biologically plausible overlap between histamine signaling and GH secretion

That is mechanistic inference, not clinical trial evidence. A woman choosing to take this combination deserves to know that distinction. The precautions here are not alarmism; they are the appropriate response to a genuine data vacuum.

Questions to Ask Your Prescriber Before Starting

Bring this list to your next telehealth appointment:

• What is my baseline IGF-1, and what target range are we aiming for?
• Which form of CJC-1295 are you prescribing (with DAC or without), and how does that change my dosing schedule?
• What contraception am I using, and does it interact with quercetin via CYP3A4?
• Do any of my other medications (statins, thyroid drugs, hormones) require dose adjustment if I add quercetin?
• How will we monitor for over-suppression of my natural GH axis over time?